The new service chief will report to the Deputy Division Head of Cellular Therapy and the Head of DHM, and will have programmatic oversight and responsibility for the service and faculty. This service will operate in a matrix reporting structure, with providers practicing in disease specific services, along with the Cellular Therapy Service. The service chief will work to shape the strategic and programmatic priorities for the service, clinical excellence, clinical operational efficiency, talent acquisition and retention, research, grant funding, professional development, mentorship and teaching. The administrative infrastructure available in the service will allow the service chief to maintain both a clinical practice and an independent research program.

At a minimum, qualified candidates should be/should have an:

• Nationally recognized clinician as well as a leader in clinical, translational, laboratory based or population science
• Extensive knowledge of the clinical care of patients with Immune Effector Cells, with experience in both Hematologic Malignancy and Solid Tumor care.
• Board-eligible or board-certified in Medical Oncology and/or Hematology
• Eligible for licensure in New York State and New Jersey

MSK has a strong commitment to enhancing the diversity of its faculty and staff. Applicants from diverse racial, ethnic, and cultural backgrounds are encouraged to apply. MSK offers competitive salaries and benefits. Interested applicants should send curriculum vitae and letter of interest to Valentina Salkow at salkowv@mskcc.org and Monchell Johnson at johnsom7@mskcc.org

#LIPOST